GlassScriptPhysician profile
Ashley Matthews
NPI 1649705518
$8,518.52
in general payments reported to CMS, 2019-2025
29 companies · $2,497 in 2025
The $2,497 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $992 · 2023: $2,617 · 2024: $2,031 · 2025: $2,497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,651 · Education: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,651.49 |
| Education | $493.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,132.63 | 2022-2025 | |
| Janssen Biotech, INC. | $1,205.73 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $990.36 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $879.35 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $787.74 | 2021-2025 | Ilumya, Blu-U, Odomzo |
| Leo Pharma INC. | $329.26 | 2021-2025 | Adbry |
| Ucb, INC. | $289.30 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $269.39 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Incyte Corporation | $217.89 | 2021-2025 | Opzelura |
| Genzyme Corporation | $212.93 | 2022-2025 | |
| Amgen INC. | $194.16 | 2022-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $156.94 | 2022-2024 | Sotyktu |
| Mayne Pharma Commercial LLC | $105.29 | 2025 | |
| Kerecis Limited | $96.77 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.91 | 2023-2024 | Spevigo, Cyltezo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $91.56 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.93 | 2023-2025 | Jublia, Cabtreo, Siliq |
| Galderma Laboratories, L.P. | $75.32 | 2024-2025 | Nemluvio, Aklief |
| Botanix Sb INC | $56.33 | 2025 | Sofdra |
| Organon LLC | $48.89 | 2025 | Vtama |
| Cipher Pharmaceuticals US LLC | $36.34 | 2025 | Spinosad, Natroba |
| Pfizer INC. | $33.18 | 2022-2025 | |
| Convatec INC. | $25.91 | 2025 | |
| Genentech USA, INC. | $20.41 | 2022 | |
| Fresenius Kabi USA, LLC | $19.64 | 2023 | |
| Dermavant Sciences, INC. | $18.48 | 2023 | Vtama |
| Allergan, INC. | $18.39 | 2022 | |
| Epi Health, LLC | $15.13 | 2022 | |
| Verrica Pharmaceuticals INC. | $14.36 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.